University of Thessaly (UTH)
Ψωρίαση και αυξητικοί παράγοντες, προ και μετά τρίμηνης χορήγησης βιολογικής θεραπείας
Abstract
dc:descriptionPlaque psoriasis is the most common form of psoriatic disease, corresponding to a chronic inflammatory skin disorder. Plaques psoriasis typically appear as raised, inflamed, and scaly red patches of skin covered with a silvery white buildup of dead skin cells or scale. Plaques can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso. Plaques generally appear symmetrically on the body, affecting the same areas of the body on the right and left sides. Tumor necrosis factor (TNF)-α inhibitors are considered to be effective in the treatment of psoriatic plaques, although the precise therapeutic pathway is not clear. Pro-inflammatory molecules, such as Toll-like receptor (TLR)-2 and -9 and interleukin (IL)-33, a member of the IL-1 receptor/TLR superfamily, have been found to be expressed in psoriatic plaques. The aim of the present study was to investigate whether TNF-α inhibitor treatment has an effect on the expression of IL-33 and TLR-2 and -9 in psoriatic plaques. Seventeen patients with psoriatic plaques were treated with a TNF-α inhibitor (etanercept or infliximab) for 12 weeks in an open-label study, and the transcriptional levels of IL-33 and TLR-2 and TLR -9 were determined by reverse transcription-quantitative polymerase chain reaction in paired biopsies of psoriatic plaques obtained at baseline (B) and following the 12 weeks of treatment (P). The psoriasis area severity index (PASI) score was also determined. At B, elevated IL-33 and TLR-2 mRNA levels were observed in all cases, while TLR-9 showed elevated mRNA levels in 76% of cases. At P, reductions in the mRNA levels of IL-33, TLR-2 and TLR-9 were observed, with TLR-2 and TLR-9 levels exhibiting significant reductions (P<0.0001, Wilcoxon signed-rank test). PASI scores were significantly reduced by the treatment (P<0.0001, Wilcoxon signed-rank test) and the changes in PASI scores exhibited a significant positive Pearson's correlation with the P/B mRNA expression ratios of TLR-2 or -9 in males (P<0.05), particularly in the etanercept group (P<0.0001). The findings support the efficacy of anti-TNF-α treatment on the innate immune response in psoriatic skin, with a focus on TLR-2 and -9 inhibition, suggesting their role in the pathogenic mechanism of plaque psoriasis, which may be associated with gender. In conclusions, in all patients, the PASI improved with treatment; the mean ± standard deviation PASI score was reduced from 21.2±8.8 at B to 5.0±4.8 at P (ΔPASI=16.2, P<0.0001; Fig 1A). In patients who received etanercept, the mean PASI score was decreased significantly from 20.3±6.7 at B to 5.2 ±5.3 at P (ΔPASI=15.1, P<0.0001; Wilcoxon signed-rank test). Key words: anti-tumor necrosis factor-α (anti-TNF-a), psoriatic plaques, interleukin-33(IL-33), Toll-like receptor-2 (TLR-2), Toll-like receptor-9 (TLR-9), etanercept, infliximab, quantitative polymerase chain reaction (PCR), mRNA, baseline (B), post treatment (P), psoriasis area severity index (PASI).
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Exarchou, Aikaterini
- Εξάρχου, Αικατερίνη
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55307